Trial Profile
A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Tanimilast (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Chiesi Farmaceutici
- 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 18 Oct 2012 New trial record
- 16 Oct 2012 Results reported in a Chiesi media release.